A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

This is an interventional treatment trial for Achilles Tendinopathy focused on measuring Achilles tendon; mid-portion Achilles tendinopathy; peritendon injection Read More

Inclusion Criteria:

• Written informed consent must be obtained prior to all study specific screening procedures, as close to the start of the screening period as possible.
• Presence of clinically (local Achilles tendon pain on tendon-loading activities, pain on palpation at the level 2-6 cm proximal to the calcaneal insertion) and ultrasound (local tendon thickening with hypoechogenicities and irregular fibre orientation) or MRI diagnosed mid-portion Achilles tendinopathy with symptoms present ≥8 weeks but <12 months at screening.
• The Achilles tendinopathy must have been refractory to at least 6 weeks of conservative treatment (physiotherapy, NSAIDS, RICE), but participants do not need to be in physiotherapy at the time of study entry.

Exclusion Criteria:

• Medical condition that would affect safety of peritendon injection (e.g., peripheral vascular disease, use of anticoagulant medication)
• History of recurrent, acute, symptomatic infections, including outbreaks of oral or genital herpes (> 2 symptomatic infections or >2 courses of anti-infective treatments required in the last 6 months; active systemic infection during last 2 weeks; known active infections (e.g. chronic or active Hepatis B, HIV) - simple cold excluded
• History or evidence of clinically significant cardiac or cardiovascular disease
• History of deep vein thrombosis, pulmonary embolism or evidence of primary or secondary hypercoagulable states
• History of surgical intervention for the treatment of tendinopathy, history of ankle surgery, ankle arthritis, traumatic, inflammation or deformity of ankle
• History of full-thickness tear or complete rupture of the Achilles tendon